Composite scaffold for tissue repair

Abstract

A synthetic composite material for tissue repair is disclosed which includes a first layer having an organic material and having side walls and external surface; and a second porous layer comprising an inorganic material and having side walls; wherein the first layer is in direct contact with the second layer and wherein the side walls of the first layer and the side walls of the second layer are coated with a third layer of the organic material.

Claims

1. A synthetic composite material for tissue repair comprising: a first sponge layer formed from an organic material optionally complexed with at least one polyanionic substance, said first sponge layer having side walls, and said first sponge layer being optionally seeded with cells; a second porous layer abutting said first sponge layer, said second porous layer formed from an inorganic material, and said second porous layer having side walls; and a third layer abutting and covering said side walls of said first sponge layer and said side walls of said second porous layer, said third layer formed from said organic material of said first sponge layer; wherein said first sponge layer and said second porous layer are joined at said abutment and define an interconnection zone: wherein said interconnection zone comprises said organic material of said first sponge layer penetrating and filling the pores of said inorganic material of said second porous layer for a distance extending past said abutment resulting in a mixture of said organic material and the inorganic material being co-present in said interconnection zone, said distance extending past said abutment up to 3 mm into said second porous layer; and wherein said first sponge layer and said second porous layer each have an exposed surface most distal from said abutment.

2. The synthetic composite material according to claim 1, wherein said first layer has a thickness of 0.1-20 mm, said second layer has a thickness of 2-400 mm, said third layer has a thickness of 0.1-2 mm high, said interconnection zone has a thickness of 0.5-3 mm.

3. The synthetic composite material according to claim 1, wherein the organic material is selected from the group consisting of at least one collagen and derivatives thereof, chondroitin-sulphate, hyaluronic acid and derivatives thereof, polyglactin, polydioxanone, alginate, agarose, chitosan and derivatives thereof, fibrin glue, polyethylene glycol diacrylate, or a combination thereof.

4. The synthetic composite material according to claim 1, wherein the inorganic material is selected from the group consisting of hydroxyapatite, calcium sulphate, calcium silicate, calcium phosphate, magnesium silicate, metal or a combination thereof.

5. The synthetic composite material according to claim 1, wherein the second porous layer has a pore dimension between 50 um and 700 um.

6. The synthetic composite material according to claim 1, wherein the organic material of the first layer is complexed with said at least one polyanionic substance.

7. The synthetic composite material according to claim 1, wherein the first layer is seeded with said cells.

8. The synthetic composite material according to claim 7, wherein said cells are chondrocytes.

9. A composite structure comprising one or more synthetic composite material according to claim 1.

10. A synthetic bone material, bone implant, bone graft, bone substitute, bone scaffold, filler, coating or cement comprising the synthetic composite material according to claim 1.

11. A synthetic skin material, plaster, bandage comprising the synthetic composite material according to claim 1.

12. The synthetic composite material according to claim 6, wherein the metal is magnesium or titanium.

13. The synthetic composite material according to claim 1, wherein the inorganic material is hydroxyapatite.

14. The synthetic composite material according to claim 1, wherein said synthetic composite material has a percentage by volume of 46 to 72 percent for said first layer, 19 to 36 percent for said second layer, and 9 to 18 percent for said interconnection zone.

15. The synthetic composite material according to claim 9, wherein said at least one polyanionic substance is a signaling molecule.

16. The synthetic composite material according to claim 1, wherein said signaling molecule is a growth factor selected from the group consisting of transforming growth factor-1, bone morphogenetic proteins and insulin growth factor-1.

17. A method of treatment of osteochondral defects comprising implanting in a subject in need thereof the synthetic composite material according to claim 1.

18. A method of treatment of skin defects comprising applying on a subject's skin in need thereof the synthetic composite material according to claim 1.

Description

(1) The invention will now be illustrated by means of non-limiting examples in reference to the following figures.

(2) FIG. 1: A schematic representation of the procedure for the osteochondral substitute fabrication (see text).

(3) FIG. 2: A) Six chondral lesions were done in the right trochlea of six pigs. B) The 6 chondral biopsies were digested and the autologous chondrocytes were isolated; then the cells were expanded in culture and finally seeded in the collagenic portion of the osteochondral substitute; the seeded substitutes were cultured in chondrogenic medium for 3 weeks and then implanted. C) With a second surgery, the repairing tissue formed in the six lesions was removed generating an osteochondral lesion having the same dimensions of the scaffold; each animal received 2 seeded scaffolds, 2 unseeded scaffolds, while 2 lesions were left untreated.

(4) FIG. 3: Characteristics of the bilayered scaffold. (a) Three bilayered scaffolds after first lyophilisation Lyo 1; (b) integration between the collagen and the hydroxyapatite layers; (c) a scaffold at the end of the fabrication process (Lyo 2) before the implantation in the animal.

(5) FIG. 4: ICRS Macroscopic Score that showed significant differences among the untreated group (no scaffold) and the groups with scaffolds seeded (cells) and unseeded (no cells). In particular, values were significantly lower in the seeded scaffold with respect to the untreated group and the unseeded scaffold group, suggesting the lack of benefit of the use of cells seeded in the scaffold in facilitating the healing process.

(6) FIG. 5: ICRS II parameters (cell morphology and surface assessment) that showed significant differences among the three experimental groups (Untreated lesion (untreat); Unseeded scaffold (cells) and Seeded scaffold (+cells). In particular, values were significantly higher in the unseeded scaffold group with respect to the seeded one and the untreated group, suggesting a more efficient repair in the lesions treated with the scaffold alone.

(7) FIG. 6: SAFRANIN-0 staining of the repaired lesion: A) Untreated lesion; B) Unseeded scaffold; C) Seeded scaffold in the 1/3 superficial and 2/3 deep zones.

(8) FIG. 7: SAFRANIN-0 staining of the repaired lesion: A,D) Untreated lesion; B,E) Unseeded scaffold; C,F) Seeded scaffold. A-C: Superficial zone; D-F: Deep zone.

(9) FIG. 8: Collagen 2 (A, B, C) and 1 (D, E, F) immunohistochemical staining of osteochondral defects. All figures have the same scale bar of 200 m. Collagen type 2. A) Untreated group; scarce immunoreactivity to collagen type 2 in the central zone of the critical defect; A1) immunonegative reactivity in the central area of the defect, where blood vessels are also present; A2) immunonegative reactivity in the deep area where the bone remodeling area is present. B) Scaffold group: scarce immunopositivity in the central zone of the defect, but a high reactivity to collagen 2 in the lateral part of the osteochondral defect is well evident; B1) scarce immunopositivity at a superficial level, with clear fiber fragmentation; B2) strong lateral immunopositivity. C) Scaffold+cells group: an increasing immunopositivity from the superficial to the deep level of the chondral defect is evident; C1) scarce immunopositivity at the superficial level of the chondral defect; C2) strong immunopositivity at a deep level of the chondral defect. Collagen type 1. D) Untreated group: immunonegative reaction to collagen 1 in the whole zone of the osteochondral defect; D1) immunonegative reaction at a superficial level; D2) immunonegative reaction in the area of bone regeneration, where the fibers appear to be fragmented. E) Scaffold group: scarce immunopositivity in the surgical defect area; E1) the distribution of immunopositive bundle fibers is evident; E2) strong immunoreactivity in the area of bone regeneration. F) Scaffold+cells group: very scarce immunoreactivity to collagen 1 at a superficial level; F1) the immunoreacitvity becomes stronger when it comes to a deep level of the defect; F2) immunoreactive fiber bundles in the area of bone regeneration.

(10) FIG. 9: Biochemical analysis of the repaired lesion: DNA quantification as index of cellularity (g/mg wet weight); GAGs quantification (g/mg wet weight); GAGs/DNA ratio (g/g). A) Biochemical analysis of the experimental samples with respect to the native cartilage. B) Biochemical analysis of the experimental samples with respect to the different treatments.

(11) FIG. 10: A schematic representation of the procedure for the osteochondral substitute fabrication, which allows for the obtainment of different complex systems (see text). Different assembling configurations of the bi-layered scaffolds (obtained by Lyo 1) by using different molds B. Mold B for: A) a single bi-layer scaffold; B) a single layer of bi-layered scaffolds; C) two layers of bi-layered scaffolds; D) single and multi-layers of bi-layered scaffolds of different dimensions and shape (circle and squared section). E) The composite scaffolds made of a different number of bi-layered scaffold used, as example, for percentage calculations in Table I.

DETAILED DESCRIPTION OF THE INVENTION

Materials and Methods

(12) Scaffold Fabrication

(13) A novel bilayer scaffold was developed. The scaffold is a three-dimensional structure made of superior collagen scaffold partially penetrating into a bottom hydroxyapatite scaffold. The two fabrication processes of respectively collagen and hydroxyapatite scaffold were separately optimised in previous studies [22]. In order to obtain a partial but strong interconnection between the collagen and hydroxyapatite part of the ostechondral substitute, a multi-step procedure was assessed that is described in the six steps reported below (FIG. 1).

(14) (1) Fabrication of the porous hydroxyapatite cylinders in the suitable dimensions for the in vivo test. Hydroxyapatite macrochanneled porous scaffolds were produced by a polymeric sponge templating method using a reactive sub-micron powder synthesized by hydroxide precipitation sol-gel route. The HA powder (diameter range 50-200 nanometers) was calcined in air at 900 C. for 60 min before use [23]. The porous hydroxyapatite scaffolds were obtained by impregnating small cylinders (diameter=9.7 mm, height=8.6 mm) of a polyurethane sponge (density of 30 Kg/m.sup.3, 25 ppi, kindly provided by ORSA Foam S.P.A. (MTP30TRAU/F1) with a slurry prepared by adding the HA powder (solid load between 50 and 80 wt %) in a polyvinyl alcohol solution (0-3 weight percentage) (Sigma Aldrich, 9002-89-5). Dolapix CE-64 (Zschimmer & Schwarz, Lahnstein, Germany) was used as a dispersant for the impregnation (range 0-1 wt %). Importantly, these values of HA powder, polyvinyl alcohol or dispersant may vary when using different types of HA, from different origin or in case of employment of different type ceramic material in order to obtain a material having similar porous morphology and mechanical characteristics. The infiltrated sponges were then gently squeezed to remove the exceeded slurry, dried for 24 hours in air, heat treated at 500 C. to burnout the sponges and finally sintered between 1200 and 1350 C. The polyurethane sponge dimensions were slightly bigger than the final desired dimensions of the biphasic substitutes in order to compensate the sintering shrinkage.

(15) (2) Fabrication via stereolithografy of a mould (mould A) for the collagen slurry lyophilisation. The mould shape and dimensions are properly designed in order to sustain the hydroxyapatite scaffold and contemporarily to allow for the lyophilisation of the collagen. More in detail, a multiwell plate (75) is designed in which every single well is made of two coaxial cylinders of different diameter. The well has a total height of 12 mm (H.sub.A) a top diameter of 8.6 mm (D.sub.A) and a bottom diameter of 8.2 mm (d.sub.A). The height of the part of the well having the smaller diameter (bottom part) is equal to 4 mm (h.sub.A). (the dimensions of the mould, the collagen part and the hydroxyapatite parts can vary, depending on the dimensions of the area to be regenerated). An interconnection zone results in which the two materials are co-present for a pre-established height. For the in vivo study here reported the two materials are co-present for 1 mm height (this height can have a variable range; generally, this can be fabricated with a range of 0.5-3 mm). The mould was fabricated in epoxy resin (accuGen 100 HC, 3D System).

(16) (3) Lyophilisation and crosslinking of the collagen scaffolds within the mould A (Lyo 1 and CrossL 1). More in detail, the collagen part was obtained by a freeze drying technique. Briefly, freeze-dried membranes of type 1 equine collagen (Antema, 911980427, kindly provided by Opocrin S.P.A, Italy) were pulverized in a refrigerate mill and the obtained collagen flakes were suspended in double distilled water in order obtain a collagen concentration of 2 wt %. Importantly, this percentage may vary from 0.5% to 5% when using different types of collagen, from different animal source or from different extraction, in order to obtain a material having similar porous morphology and mechanical characteristics. The slurry was agitated by a magnetic stirrer for two hours and poured into the mould A till a height of 1 mm was reached in the top cylinder of the well (h.sub.i). The hydroxyapatite scaffolds from step 1 were then inserted in the mould holes partially filled by collagen slurry. The samples were frozen at 40 C. at 1 C./min and freeze-dried. In order to induce a dehydrothermal (DHT) crosslinking to the collagen fibers, the samples were placed in oven at 110-130 C. under vacuum for a minimum of 48 and a maximum of 96 hours.

(17) (4) Fabrication via stereolithografy of a mould (mould B) for a second collagen lyophilisation. The mould B is designed with the aim of making a perfectly cylinder substitute of the final desired dimensions, covered all around by a very thin layer of collagen. The diameter and the height of the mould B are equal to 9.2 and 12 mm respectively. A thin layer of about 0.3 mm will result. The dimension of this thin layer of collagen around the material may vary if need, based on particular surgical condition; generally it may range from 0.1 to 2 mm. In fact, the collagen layer has the double purpose of eliminating the small step derived from the use of the mould A and facilitating the substitute insertion in the ostechondral lesion by the medical staff.

(18) (5) Lyophilisation and crosslinking of the collagen scaffolds within the mould B (Lyo 2 and CrossL 2). The biphasic substitutes from step 3 were inserted in the mould B holes, then covered all around by collagen slurry. In this case, the collagen slurry was added till the well was completely filled. The samples were frozen at 40 C. at 1 C./min and freeze-dried again (Lyo 2). A dehydrothermal (DHT) crosslinking treatment (CrossL 2) was applied to the samples using the same conditions of CrossL 1.

(19) (6) Substitutes sterilization in oven under vacuum at 160 C. for 2-4 hours.

(20) Chondrocyte Isolation, Expansion and Seeding

(21) Approval for the study was obtained from the Italian Ministry of Health.

(22) Six four-months old Landrance large white pigs were used for this study. All animals were anesthetized as follows: Telazol 100 mg/ml (Tiletamine HCl 50 mg/ml and Zolazepam HCl 50 mg/ml; Fort Dodge Animal Health, Fort Dodge, Iowa, USA) at the dosage of 1.4 mg/Kg; Xylazine HCl 100 mg/ml (Boehringer Ingelheim Vetmedica, Inc. St. Joseph, Mo., USA) at the dosage of 2.0 mg/Kg; Robinul-V 0.2 mg/ml (Glycopyrrolate; Fort Dodge Animal Health) at the dosage of 0.01 mg/Kg. After induction, anesthesia was maintained with Isoflurane (Baxter Healthcare Corporation, Deerfield, Ill., USA). The animals were then placed in the supine position. A longitudinal paramedian incision was made in the medial aspect of the right knee. The vastus medialis muscle, which completely surrounds the patella in the pig, was sectioned to expose the articular capsule. A capsulotomy was performed and the patella was dislocated laterally to expose the articular surface of the trochlear groove. Six cartilage lesions measuring 6 millimeter in diameter (chondral plugs) and extending up to the border with the calcified cartilage were produced in the medial aspect of the patellar groove with a standardized core punch (FIG. 2A). The chondral plugs were placed in 50 ml test tubes containing phosphate buffered saline and the antibiotic/antimycotic solution. The wound was then closed in layers in standard fashion. An impermeable dressing using betadine gel was applied (Viatris spa, Milan, Italy). Prophylactic antibiotic therapy was instituted using 1,200 units of penicillin G (Bicillin L-A; Wyeth Laboratories Inc. Philadelphia, Pa., USA), given on days two and four postoperatively. Pain management consisted of Duragesic 75 g/h (Fentanyl transdermal system; Janssen Pharmaceutica Inc. Titusville, N.J., USA) and 0.3 mg of buprenorphine (Buprenex injectable; Reckitt & Colman Pharmaceuticals Inc. Richmond, Va., USA). No immobilization was applied after operation and the animal was allowed to move freely.

(23) Some cartilage slices (native cartilage) harvested from the same animals were frozen as a control tissue for biochemical analysis; all other cartilage slices were digested in Ham's medium (Celbio, Pero, Mich., Italy) containing 0.1% collagenase Type 2 (DBA-Italia Srl, Segrate, Mich., Italy) and 1% of the antibiotic/antimycotic solution (10,000 units Penicillin, 10 mg Streptomycin and 25 g Amphotericin B/ml in 0.9% sodium chloride; Sigma Chemical Co., St. Louis, Mo., USA). The specimens were incubated overnight in an oscillating water bath at 37 Celsius. Undigested tissue and debris were removed by filtering the cell suspension using a 100 micron sterile filter (BD Falcon, Bedford, Mass., USA). The cell suspension obtained was centrifuged at 1400 rpm for 10 minutes. The cell pellet was washed twice in phosphate buffered saline (Celbio) and 2% antibiotic/antimycotic solution. Viability of the chondrocytes was assessed by Trypan blue staining (Sigma) and recorded as a percentage of viable chondrocytes per high power field. The exact cell count per milliliter was established using a haemocytometer. Fresh chondrocytes were plated at a concentration of 10000 cells/cm.sup.2 and cultured in DMEM (Lonza, Italia) containing 10% FBS (Euroclone), 1% glutamine (EuroClone, Milan, Italy), and 1% antibiotic/antimycotic solution (Sigma), 5 ng/ml FGF-2 (R&D Systems, Minneapolis, Minn., USA), 10 ng/ml TGF-1 (R&D Systems, Minneapolis, Minn., USA); medium was changed three times a week. After two passages, the de-differentiated chondrocytes were collected, resuspended in a solution containing bovine fibrinogen (for example 110 mg/ml, FlukaChemie GmbH, Buchs, SG, Switzerland), aprotinin (0.2 mg/ml) (Sigma), tranexamic acid (1.5 mg/ml) (Sigma) and adjusted to a concentration of 8010.sup.6 cells/ml. Then, 100 l of the fibrinogen-cell suspension was seeded onto the scaffold on the collagen layer (810.sup.6 cells/scaffold; possible range: 0.5-1610.sup.6 cells/scaffold) prepared according to the design parameters optimized previously [24]. After complete cell absorption, 100 l of thrombin (1.37 mg/ml, Chemicon International, Inc., Temecula, Calif., USA) were added in order to form fibrin glue. After 30 minutes, complete polymerization was reached and the scaffolds were placed in culture flasks for the in vitro culture. The seeded scaffolds were cultured in vitro for 3 weeks in DMEM (Lonza, Italia) containing 10% FBS (Euroclone), 1% glutamine (EuroClone, Milan, Italy), and 1% antibiotic/antimycotic solution (Sigma), ascorbic acid 50 g/ml (Sigma), 10 ng/ml TGF-3 (R&D Systems, Minneapolis, Minn., USA); medium was changed three times a week (FIG. 2B).

(24) Study Design

(25) Animals were anesthetized and positioned as previously described. A longitudinal paramedian incision was made in the medial aspect of the right knee, on the previous skin scar and duplicating the prior surgical approach. Articular capsule was open and the previously sites of cartilage harvest were identified. The repairing tissue formed in the six chondral lesions was removed and six new osteochondral lesions encircling the previous defect areas were performed with a standardized core punch measuring 8 millimeter in diameter and 9 mm in depth. Three different types of treatment were tested a) implants of bilayer scaffolds seeded with autologous chondrocytes (group cell +); b) implants of osteochondral substitute unseeded (group cell ); no implants (untreated group). Each animal was treated with two seeded bilayer scaffolds and two unseeded bilayer scaffolds; two lesions per animal were left untreated (FIG. 2C). Care was taken in randomizing treatment to all six experimental lesion sites (proximal, intermediate and distal on the medial and lateral aspects of the patellar groove). This was done to avoid influencing the reparative process from the different anatomical locations of the lesions in the patellar groove of the animal knees. The capsule was then closed and the wound was sutured in layers. Post-operative care, medications, and dressings were as previously described. The animals were able to stand on the operated leg and allowed to walk freely. Generally, all animals were able to stand and bear full weight on four legs after 24-72 hours postoperatively. Twelve weeks after implantation all animals were euthanized using an overdose of Pentobarbital (100 mg/kg IV), the knee joints opened and the repaired tissue evaluated as described below.

(26) Tissue Repair Evaluation

(27) Gross Evaluation

(28) After the opening of the joints the macroscopic appearance of the repaired tissue was examined using the ICRS Macroscopic Score [25], which evaluates the degree of defect repair, the integration to the border zone, and the macroscopic appearance. Two observers, both blind to the treatment, independently scored the specimens.

(29) Histochemical Analysis

(30) The repair areas were removed with healthy tissue surrounding the lesions. Each sample was cut in half, along the central axis of the lesions. Half sample was fixed in 10% (v/v) phosphate-buffered formaldehyde. The samples were then dehydrated in a graded 50% (v/v), 70% (v/v), 95% (v/v) and 100% (v/v) ethanol series, embedded in paraffin and cut into 4 m-thick sections. Finally, the sections were stained with SAFRANIN-0, using a standard staining protocol, for the evaluation of the morphology and GAGs deposition. Some sections were used for immunohistochemical analysis of collagen type I and II (Chondrex staining kit, Chondrex Inc, USA). After rehydration, heat-induced antigen retrieval was performed by treating the sections in citrate buffer, pH 6.0, in a microwave oven. Sections were then washed 3 times in PBS (pH 7.4). Before immunostaining, sections were treated in a 2% hyaluronidase solution (Sigma) at room temperature for 30 min. In order to block endogenous peroxidase activity, the sections were incubated in an aqueous solution of 1% H.sub.2O.sub.2 for 30 min at room temperature and then washed 3 times in PBS. Sections were incubated overnight with mouse anti-collagen type II antibody (Chondrex, Inc; 1:500). Labeled biotin secondary antibody-streptavidine peroxidase (1:500) was applied for 1 hour at room temperature. Peroxidase activity was visualized with diaminobenzidine (DAB; Dakocytomation, Milan, Italy) and H.sub.2O.sub.2 as substrates. All incubations were performed in a moist chamber at room temperature, using PBS for washes between incubation steps. Sections were counterstained with hematoxylin, dehydrated and mounted in mounting medium. Photomicrographs were taken with an Olympus BX51 microscope (Olympus, Italy) equipped with a digital camera and final magnifications were calculated. The experimental samples stained for SAFRANIN-O were analyzed at the optical microscope in order to evaluate the parameters established by ICRS II: each criterion was evaluated based on the visual analog scale and graded from 0 to 100 [26]. The obtained values were analyzed in order to highlight the statistically significant differences among the three experimental groups.
Biochemical Analyses

(31) The biochemical analysis was performed on the other half of samples for each experimental condition (1 seeded scaffold, 1 unseeded scaffold and 1 untreated lesion). The samples were digested in papain (Sigma) for 16-24 h at 60 C.; the digestion solution was composed of 125 g/mL of papain (Sigma) in 100 mM sodium phosphate, 10 mM sodium EDTA (Sigma), 10 mM cysteine hydrochloride (Sigma), 5 mM EDTA adjusted to pH 6.5 and brought to 100 mL of solution with distilled water. After the digestion, the samples were stored at 80 C. until analysis. Aliquots of the digested samples were assayed separately for proteoglycan and DNA contents. Proteoglycan content was estimated by quantifying the amount of sulphated glycosaminoglycans using the 1,9-dimethylmethylene (DMB) blue dye binding assay (Polysciences Inc., Washington, Pa., USA) and a microplate reader (wavelength: 540 nm). The standard curve for the analysis was generated by using bovine trachea chondroitin sulfate A (Sigma). DNA content was evaluated with the Quant-iT Picogreen dsDNA Assay Kit (Molecular Probes, Invitrogen, Eugene, Oreg., USA) and a fluorescence microplate reader and standard fluorescein wavelengths (excitation 485 nm, emission 538 nm, cut-off 530 nm). The standard curve for the analysis was generated using the bacteriophage lambda DNA supplied with the kit.

(32) Statistical Analysis

(33) Descriptive statistics were used to determine groups' means and standard deviations for numerical data, and analysis was performed using analysis of variance. Statistical significance was defined as a p-value of <0.05.

(34) Results

(35) Fabrication of the Substitute

(36) The collagen/hydroxyapatite substitutes were properly fabricated. In FIG. 3 pictures of bilayered scaffolds after first lyophilisation (a), after integration between the collagen and the hydroxyapatite layers (b) at the end of the fabrication process before the implant in the animal (c), are reported.

(37) Morphology and Scoring of the Repaired Lesions

(38) At the gross evaluation of specimens, all grafts were still in their original location. The ICRS macroscopic score was significantly lower in the cell + group when compared with cell and untreated group (p<0.05 and p<0.005, respectively). No statistically significant difference was detected between cell and untreated group (FIG. 4). The obtained data demonstrate a more efficient repair in the untreated lesions and in the lesions treated with the scaffold alone, suggesting a strong contribute of endogenous bone marrow cells in the regeneration of the osteochondral lesion. Such endogenous contribute was reduced in the seeded scaffolds probably as a consequence of the chondral collagen phase where autologous chondrocytes had been seeded with fibrin glue and they had already produced a matrix network at the moment of the implantation, leading to a less efficient colonization of the chondral phase. Histological evaluation showed the presence of a newly formed repair tissue, with areas of fibroblast-like tissue and areas of hyaline-like tissue in all groups. The three different experimental groups showed significant differences in scores only in two parameters; in particular, the unseeded osteochondral scaffolds showed higher values (P<0.05) for cell morphology and for the surface/superficial assessment, with respect to both the seeded scaffolds and the untreated lesions (FIG. 5). As demonstrated by the histochemical analysis with SAFRANIN-O, the unseeded scaffolds were characterized by a linear superficial layer with an uniform GAGs distribution throughout the lesion site (FIG. 6A); moreover, the cells were chondrocytes-like and some of them were surrounded by lacunae (FIG. 7A,D). The seeded scaffolds and the repairing tissue of the untreated lesions showed irregular superficial layers with hollows (FIG. 6B,C); in the superficial layer, the cell morphology is mainly fibroblast-like with no lacunae (FIG. 7B,C), while in the deeper region some cells showed a chondrocyte-like phenotype, but no lacunae were present around them (FIG. 7E,F). Immunohistochemical analysis for collagen type 2 showed in the untreated group a scarce immunoreactivity, while in the cell group a high reactivity in the lateral part of the defect was observed; additionally, in the cells + group an increasing immunopositivity from the superficial to the deep level of the defect was also detected. The evaluation of collagen type 1 showed in all groups a scarce immunopositivity that becomes stronger in a deep level of the defect only in the cell + group (FIG. 8).

(39) Biochemical Analysis of the Repaired Lesions

(40) The experimental samples were digested in papain in order to measure either the DNA content, an index of cellularity, or GAGs production as a marker of the extra-cellular matrix. With respect to native cartilage, only the seeded osteochondral scaffolds showed a significative (P<0.05) higher cellularity (FIG. 9A) while GAGs production and GAGs/DNA ratio were lower (P<0.05) in all the experimental groups.

(41) Comparing the different experimental groups, the seeded scaffolds showed a significative higher cellularity while the GAGs/DNA ratio was higher in the untreated lesions with respect to the seeded and unseeded scaffolds (P<0.05); no differences were observed in GAGs production among the different experimental groups (FIG. 9B).

DISCUSSION

(42) In the present invention, a novel three-dimensional biphasic substitute made of an organic/inorganic hybrid material was developed. The scaffold is preferably made of the combination of a collagen type 1 sponge, previously characterized for its compatibility and application as a supporting materials for cartilage tissue engineering applications, and a HA component. The bilayer scaffold was successfully produced thanks to the fabrication of a properly designed mould via stereolithography that allowed for obtaining an interconnection zone where the two materials (collagen and HA) were co-present for a pre-established thickness (FIG. 1). In particular, for the in vivo study here reported the two materials are co-present for 1 mm height, but this height can have a variable range: generally, this can be fabricated with a range of 0.5-3 mm. This particular structure has the advantage of allowing for a greater integration of the two materials and also, duplicating the native tissues, disposing the ideal substratum for a proper re-population following in vivo implantation. Additionally, the second novelty introduced, i.e. the fabrication via stereolithografy of a second mould for a further collagen lyophilisation around the HA cylinder, has the double aim of both improving the collagen/hydroxyapatite integration and facilitating the substitute insertion in the osteochondral lesion, allowing for a certain degree of change in the diameter of the cylinder through a different hydration. Osteochondral defects created in the surface of the trochlea of adult pigs were treated by implanting a biphasic scaffold, which were either seeded with autologous chondrocytes or left unseeded. The use of collagen type 1 sponges has been already introduced by several groups for the in vitro engineering of cartilage [27-30] demonstrating that this biocompatible material can support chondrocytes survival and synthetic activity during time with the consequent maturation of the scaffold into a chondral substitute. Some works introduced the combination of fibrin glue to ameliorate scaffold seeding and maturation [31,32]; in particular, Malicev et al. combined fibrin glue with collagen type 1 sponge improving scaffold seeding and the in vitro maturation [33]. The bone phase was left unseeded allowing the mesenchymal stem cells from the adjacent bone marrow to migrate following the implantation and undergo an osteogenic differentiation.

(43) The overall results of the authors' study, at 3 months follow-up, showed a certain discrepancy between macroscopic and histological scores. In particular, the ICRS macroscopic score was significantly lower in the cell + group when compared with cell and untreated group; so, at early repair time, the use of chondrocytes did not seem to provide an advantage over the use of a scaffold alone. The intrinsic limit of Macroscopic analysis is related to the superficial evaluation of the sample wherein the results are obtained by examining the external aspects of the samples. Thus, the differences in the results evaluated with Macroscopic analysis and histological analysis are due to the different characteristics of the two methodology approaches. Moreover, at the histological evaluation, the repair induced by the acellular scaffold was better regarding the histological aspect of the superficial layer and the morphology of cells, demonstrating that the scaffold was able to allow the colonization and the maturation of the cells deriving from the local sources. So, the structure of the scaffolds permitted the migration of stem cells and their subsequently chondrogenic differentiation. The authors cannot exclude, however, the contribution of other cells deriving from blood or from the surrounding tissues, which were able to differentiate into a cartilaginous or fibrocartilaginous phenotype in the joint environment. The scaffold seeded with autologous chondrocytes promoted the formation of a repairing tissue with high cellularity but low GAGs production, suggesting a low chondrocytes activity. So, at the experimental time of this study, the quantity and the quality of the repaired tissue was far to be similar to the native cartilage. However, the immunohistochemical analysis revealed in the cells + group an increasing immunopositivity for the collagen type 2 from the superficial to the deep level of the defect, showing a more hyaline aspect of the repaired tissue, compared with the others groups.

(44) In conclusion, this study showed that the bilayer scaffold of the present invention is easy to handle for surgical implant and stable in the implant site; at the end of experimental time, no signs of synovitis were revealed and all implants were well integrated to the surrounding tissue. The quality of the repaired tissue produced within the bulk of the unseeded osteochondral scaffolds demonstrated the potential of this material for one-step procedure for articular cartilage repair.

REFERENCES

(45) 1. Pan J, et al. J Orthop Res. 2009 October; 27(10):1347-52 2. Mente P L, Lewis J L. J Orthop Res. 1994 September; 12(5):637-47. 3. Madry H, et al. Knee Surg Sports Traumatol Arthrosc. 2010 April; 18(4):419-33. 4. Westacott C. J Musculoskelet Neuronal Interact. 2002 December; 2(6):507-9. 5. Lories R J, Luyten F P. Nat Rev Rheumatol. 2011 January; 7(1):43-9. 6. Ding M. ActaOrthop Suppl. 2010 February; 81(340):1-53 7. Bijlsma J W, Berenbaum F, Lafeber F P. Lancet. 2011 Jun. 18; 377(9783):2115-26 8. Sellam J, Berenbaum F. Nat Rev. Rheumatol. 2010 November; 6(11):625-35. 9. Intema F, et al. 2010 May; 18(5):691-8. 10. Intema F, et al. J Bone Miner Res. 2010 July; 25(7):1650-7 11. Mitchell N, Shepard N. J Bone Joint Surg Am. 1976 March; 58(2):230-3 12. Steadman J R, et al. Orthopade. 1999 January; 28(1):26-32. German. 13. Hangody L, et al. Orthopedics. 1998 July; 21(7):751-6. 14. J. S. Temenoff, A. G. Mikos. Biomaterials, 21 (2000) 431-440. 15. D. Schaefer et al. Arthritis Rheum., 46 (2002) 2524-253. 16. A. Tampieri, et al. Biomaterials, 29 (2008) 3539-46. 17. Gun-II I, et al., Tissue Engineering 2010 16 (4):1189-1201. 18. Maehara H, et al. J Orthop Res. 2010 May; 28(5):677-86. 19. J. M. Oliveira, et al. Biomaterials, 27 (2006) 6123-37. 20. Xue D, et al. J Biomed Mater Res A. 2010 July; 94(1):259-70. 21. Qu D, et al. J Biomed Mater Res B Appl Biomater. 2011 January; 96(1):9-15. 22. Gervaso F, et al. Key Engineering Materials, Vols. 493-494, pp 890-895, 2012) 23. Gervaso F, et al. Int. J. Appl. Ceram. Technol., 9 [3] 507-516 (2012) 24. Deponti D, et al. Tissue Eng Part A, June; 18(11-12):1109-22, 2012, 25. van den Borne M. P. J. et al. Osteoarthritis and Cartilage 2007 Dec. 15(12) 1397-402 26. Mainil-Varlet P, et al. Am J Sports Med. 2010 May; 38(5):880-90. 27. Roche S et al. Biomaterials. 2001 January; 22(1):9-18. 28. Lu H, Ko Y G, Kawazoe N, Chen G. Biomaterials. 2010 August; 31(22):5825-35. 29. Oliveira S M, et al. J Biomed Mater Res A. 2010 August; 94(2):371-9. 30. Mizuno S, Allemann F, Glowacki J. J Biomed Mater Res. 2001 Sep. 5; 56(3):368-75. 31. Wang W, et al. Biomaterials. 2010 August; 31(23):5953-65. 32. Chou C H, et al. J Biomed Mater Res A. 2007 Sep. 1; 82(3):757-67. 33. Malicev E et al. Biotechnol Bioeng. 2007 Feb. 1; 96(2):364-70.